Nine Neuroimaging-AI Endophenotypes Unravel Disease Heterogeneity and Partial Overlap across Four Brain Disorders: A Dimensional Neuroanatomical Representation

Junhao Wen[1,*], Ioanna Skampardoni[2], Ye Ella Tian[3], Zhijian Yang[2], Yuhan Cui[2], Guray Erus[2], Gyujoon Hwang[2], Erdem Varol[4], Aleix Boquet-Pujadas[1], Ganesh B. Chand[5], Ilya Nasrallah[2], Theodore Satterthwaite[6], Haochang Shou[2], Li Shen[7], Arthur W. Toga[8], Andrew Zalesky[3], Christos Davatzikos[2,*]

[1]Laboratory of AI and Biomedical Science (LABS), University of Southern California, Los Angeles, California, USA
[2]Artificial Intelligence in Biomedical Imaging Laboratory (AIBIL), Center for AI and Data Science for Integrated Diagnostics (AI²D), Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
[3]Melbourne Neuropsychiatry Centre, Department of Psychiatry, Melbourne Medical School, The University of Melbourne, Melbourne, Victoria, Australia
[4]Department of Computer Science and Engineering, New York University, New York, USA
[5]Department of Radiology, School of Medicine, Washington University in St. Louis, St. Louis, MO, USA
[6]Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
[7]Department of Biostatistics, Epidemiology and Informatics University of Pennsylvania Perelman School of Medicine, Philadelphia, USA
[8]Laboratory of Neuro Imaging (LONI), Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Los Angeles, California, USA

*Corresponding authors:
Junhao Wen, junhao.wen89@gmail.com
2025 Zonal Ave, Los Angeles, CA 90033, United States
Christos Davatzikos, christos.davatzikos@pennmedicine.upenn.edu
3700 Hamilton Walk, 7th Floor, Philadelphia, PA 19104, United States

Word counts: 5669 words

Abstract

Disease heterogeneity poses a significant challenge for precision diagnostics. Recent work leveraging artificial intelligence has offered promise to dissect this heterogeneity by identifying complex intermediate brain phenotypes, herein called dimensional neuroimaging endophenotypes (DNEs). We advance the argument that these DNEs capture the degree of expression of respective neuroanatomical patterns measured, offering a dimensional neuroanatomical representation for studying disease heterogeneity and similarities of neurologic and neuropsychiatric diseases. We investigate the presence of nine such DNEs derived from independent yet harmonized studies on Alzheimer's disease (AD1-2)[1], autism spectrum disorder (ASD1-3)[2], late-life depression (LLD1-2)[3], and schizophrenia (SCZ1-2)[4], in the general population of 39,178 participants in the UK Biobank study. Phenome-wide associations revealed prominent associations between the nine DNEs and phenotypes related to the brain and other human organ systems. This phenotypic landscape aligns with the SNP-phenotype genome-wide associations, revealing 31 genomic loci associated with the nine DNEs (Bonferroni corrected P-value $< 5\text{x}10^{-8}/9$). The DNEs exhibited significant genetic correlations, colocalization, and causal relationships with multiple human organ systems and chronic diseases. A causal effect (odds ratio=1.25 [1.11, 1.40], P-value=$8.72\text{x}10^{-4}$) was established from AD2, characterized by focal medial temporal lobe atrophy, to AD. The nine DNEs, along with their polygenic risk scores, significantly enhanced the predictive accuracy for 14 systemic disease categories, particularly for conditions related to mental health and the central nervous system, as well as mortality outcomes. These findings underscore the potential of the nine DNEs to capture the expression of disease-related brain phenotypes in individuals of the general population and to relate such measures with genetics, lifestyle factors, and chronic diseases. All results are publicly available at https://labs-laboratory.com/medicine/.

Main

Disease heterogeneity[2,3,5–10] has been a significant challenge for precision medicine[11]. A new era powered by artificial intelligence (AI) and large-scale, multi-omics biomarkers may enable us to quantify individualized liability for various brain diseases[12,13]. Recent work has leveraged semi-supervised clustering methods (**Fig. 1a** and **Supplementary eMethod 1**) to tackle this challenge. These methods characterize disease heterogeneity by constructing a mapping or transformation from a reference group (e.g., healthy controls) to a target group (i.e., patients with a specific disease). In clinical neuroscience, these methods can quantify deviation from typical brain structure measured by T1-weighted magnetic resonance imaging (MRI)[1–4]. They represent disease-related neuroanatomical heterogeneity via multiple low-dimensional categorical subtypes associated with specific patterns of brain change relative to the reference group. Instead of focusing on the categorical subtypes, we investigated their corresponding continuous phenotypes (i.e., dimensions)[14], given that many chronic brain diseases develop along a continuous spectrum. Each neuroanatomical pattern's level of expression, therefore, serves as a dimensional AI-derived biomarker pertinent to the respective disease.

Previous heterogeneity research has primarily focused on within-disease heterogeneity[2,3,5–10]. However, this approach neglects the shared disease mechanisms, genetics, and clinical manifestations among different brain diseases. Conversely, while several studies have investigated the shared genetic components across various brain diseases, they have overlooked the important aspect of disease heterogeneity within each condition[15,16]. As such, a broad perspective is required to investigate disease heterogeneity simultaneously, spanning multiple neurodegenerative and neuropsychiatric disorders. This holistic approach aids in understanding the commonalities and interrelationships between these brain diseases and the multi-organ systems of humans[17]. Such an effort could simultaneously capture neurobiological heterogeneity within disorders and explain shared features, mechanisms, and risk factors across disorders. Ultimately, unraveling neurobiological heterogeneity within neuropsychiatric syndromes and explaining co-morbidity among them promises to accelerate more effective diagnosis, treatment, and prevention strategies.

These AI-derived biomarkers capture disease-specific neuroanatomic heterogeneity. However, whether these biomarkers are present in the general population, potentially simultaneously, remains unknown. Here, we sought to measure the presence of multiple AI-based signatures in the general population, delineate common mechanisms among them, and shed light on their relationship with other human organ systems[18,19]. To do this, we capitalized on nine imaging biomarkers recently derived from regional gray matter (GM) volumetrics derived from several large-scale disease-focused consortia, including ADNI[20] for Alzheimer's disease (AD1-2[1]), ABIDE[21] for autism spectrum disorder (ASD1-3[2]), LLD for late-life depression older than 60 years old (LLD1-2[3]), and PHENOM[4] for schizophrenia (SCZ1-2[4]). Utilizing semi-supervised clustering and representation learning methodologies[22], we obtained nine imaging biomarkers capturing the neuroanatomical diversity across the four distinct brain diseases. AD1 and AD2 illustrate distinct atrophy patterns in the overall brain and medial temporal lobe, respectively[1]. ASD1, ASD2, and ASD3 showcase reduced overall volume, expanded subcortical volume, and increased cortical volume[2]. LLD1 and LLD2[3] exhibit augmented subcortical volume and overall brain atrophy, respectively. Finally, SCZ1 and SCZ2[4] display global brain atrophy and expanded basal ganglia volume. We first conceptualized these biomarkers as the dimensional neuroimaging endophenotypes (DNE), seeking to test the endophenotype hypothesis in psychiatry[23–25], which suggests that such measurable intermediate

biomarkers (i.e., the endophenotypes) serve as intermediate phenotypes between genetics and
clinical symptoms of the disease. They are thought to be more closely related to the underlying
etiology and genetics than the complex clinical symptoms or the disease itself. Furthermore, the
concept of dimensional representation reinforces the idea that diseases like AD progress along a
continuous spectrum. As such, categorizing disease heterogeneity into distinct subtypes
overlooks the presence of co-existing patterns within the same individuals (refer to **Method 2a**
and **Supplementary eMethod 1a** for details).
We evaluated the manifestation of the nine DNEs in the general population using the
neuroimaging and genetic data available in the UK Biobank study[26] (UKBB, **Method 1**). The
four pre-trained disease-specific AI models (**Method 2**) were applied to the 39,178 UKBB
participants with both brain MRI[27] and genetic[28] data. To delineate the phenotypic landscape of
the nine DNEs, we first tested whether the neuroanatomical patterns of the nine DNEs are
present in the UKBB general population. Subsequently, we conducted a phenome-wide
association study (PWAS, **Method 3**) to establish associations between the nine DNEs and 611
UKBB phenotypes, including brain imaging-derived phenotypes (IDPs), traits related to multiple
human organ systems, cognition, and lifestyle factors. We performed a genome-wide association
study (GWAS, **Method 4**) linking the nine DNEs to 6,477,810 quality-checked common single
nucleotide polymorphisms (SNPs) to depict their genetic architecture. Furthermore, we
conducted analyses to investigate genetic correlations, colocalization, and causal relationships
between the nine DNEs, nine human organ systems[17], and several chronic diseases. Finally, we
assessed the ability of the nine DNEs and their corresponding polygenic risk score (PRS) to
predict 14 systemic disease categories, 8 cognitive scores, and mortality (**Method 5**).
123

Results

125 Our analytic framework involves computational genomics, statistical methods, and machine
126 learning to elucidate the phenotypic landscape and genetic architecture of the nine DNEs, as
127 illustrated in **Fig. 1**.
128

129   **Figure 1**: Study workflow

130
a) The concept of semi-supervised learning methods used in this study. These AI methods model
the patterns and transformations from the healthy control (CN) to the patient (PT) domain, thus
capturing variations related to underlying disease pathology. Nine DNEs previously published[1–4]
from four disease-focused, case-control studies were investigated. **b**) The expression of the nine
DNEs in the UK Biobank (UKBB) general population. The trained models were then applied to
the UKBB population to quantify the expression of the neuroanatomical patterns of the nine
DNEs at individual levels; a higher DNE score indicates a greater expression
(manifestation/presence) of the respective neuroanatomical pattern. For example, the blue
samples express predominantly AD2, whereas the pink samples express predominantly SCZ2.
The kernel density estimate for each DNE is shown. Of note, AD1-2 DNEs are from the Surreal-
GAN[14] model and others from the HYDRA[29] model, resulting in varying DNE score ranges by
modeling. Overall, lower scores imply milder imaging pattern expressions. **c**) Phenome- and
genome-wide analyses were performed on the nine DENs. Phenome-wide association studies

(PWAS) were conducted to associate the nine DNEs with phenotypes across nine organ systems,
cognition, and lifestyle factors. Genome-wide association studies (GWAS) were performed to
investigate associations between the nine DNEs and common genetic variants (SNPs). Finally,
the nine DNEs and their polygenic risk scores predicted 14 disease categories (ICD-10-based), 8
cognitive scores, and mortality. CN: healthy control; PT: patient.
149
All nine DNEs are evident in the general population

We tested whether the neuroanatomical patterns defined in the four disease populations could be
found in the general population. We applied the DNE models pre-trained for each disease
population to the UKBB general population to measure the degree of expression of each DNE at
the individual level. The imaging data from the four disease populations and the UKBB general
population were first statistically harmonized via the iSTAGING consortium[30] and then linearly
corrected in the AI models for common confounders like demographics to alleviate potential
domain shifts[31].
We first summarize the neuroanatomical patterns of the nine DNEs (**Fig. 2a** and **Method**
3b). Overall, the original patterns identified in the disease populations[1–4] manifest in the general
population. AD1 exhibits a pattern of brain atrophy (i.e., negative correlation) across various
brain volumes, while AD2 involves focal atrophy of the medial temporal lobe. ASD1 captures a
pattern of lower GM volumes in several subcortical regions, including the pallidum, amygdala,
and putamen, whereas ASD2 reflects a pattern of relatively larger GM volumes (i.e., positive
correlation) in subcortical regions. ASD3, conversely, is characterized by relatively larger GM
volumes in several cortical areas, including the insula. LLD1 (positive correlation) and LLD2
(negative correlation) are characterized by concomitant patterns of regional GM volumes,
prominently involving the middle frontal gyrus, the insula, and the thalamus. For schizophrenia,
a widespread pattern of reduced brain volumes (e.g., insula) is associated with SCZ1, whereas
SCZ2 displays increased volumes of the putamen and pallidum. The details of the P-value,
sample sizes, and β values of the linear regression are presented in **Supplementary eFile 1** (from
disease-specific populations[1–4]) and **2** (from UKBB).
The nine DNEs showed different strengths of expression in the general population
relative to what is seen in the disease populations from which they were derived. These
differences were statistically significant except for ASD2, after correcting for multiple
comparisons using the Bonferroni method (**Fig. 2b**). For instance, AD1, characterized by diffuse
brain atrophy in the ADNI data, showed a significant under-expression (i.e., a smaller mean of
the DNE score) in the general population. Conversely, the subcortical atrophy pattern originally
identified in ASD1 from the ABIDE data displayed a significant over-expression (i.e., a larger
mean of the DNE score) in the participants from the general population.
We then tested whether the nine DNEs differed between the healthy control and disease
groups (AD, ASD, LLD, and SCZ; refer to **Method 1** for detailed definitions) in the general
UKBB population. Compared to the healthy control group (*N*=6390), a small proportion of
patients with the four brain diseases showed significant differences (two-sample t-test) for AD1-
2 (*N*=23), LLD1-2 (*N*=1329), and SCZ1-2 (*N*=23), except for ASD1-3 (only 6 ASD patients in
this population). For example, AD2, characterized by focal medial temporal lobe atrophy, had a
significantly lower mean of DNE in the healthy control (0.29±0.19) compared to the AD patient
groups (0.45±0.27; P-value=1.1x10^{-4}). Detailed statistics for all nine DNEs are presented in
Supplementary eTable 1.

These results proved that the nine DNEs manifest in the general population and convey
disease-specific information about the four brain diseases. The contrast in their expression (i.e.,
over- and under-expression) between the disease-specific and UKBB general populations is
expected and underscores their potential relevance as sub-clinical or vulnerability quantitative
indices.
194
The nine DNEs exhibit phenotypic associations with traits beyond the brain

To delineate their phenotypic landscape, we associated the nine DNEs with 611 phenotypes in
UKBB. To avoid circularity, the PWAS did not include the 119 GM ROIs derived from T1-
weighted MRI, from which the nine DNEs were derived. Out of the 611 additional clinical traits
spanning multiple organ systems, cognition, and lifestyle factors, we discovered 1818 significant
associations after applying the Bonferroni correction (P-value < 0.5/611) (**Fig. 2c**,
Supplementary eFile 3, and **Method 3c**).
Of the 1818 significant associations, 91% were related to the brain. For example, the
mean intracellular volume fraction in the superior frontal-occipital fasciculus derived from the
multi-shell NODDI[32] model was significantly associated with AD1 [β=-0.67±0.02, -$\log_{10}$(P-
value) > 300]. Multiple DNEs were significantly associated with the biological age gap (BAG:
AI-predicted age minus chronological age) of the brain [e.g., SCZ2: β=0.19±0.01, -$\log_{10}$(P-
value)=50.10]. Furthermore, 2% of the phenotypes related to the musculoskeletal system were
associated with the nine DNEs. The nine DNEs were also largely associated with many
phenotypes related to mental health (1%). For example, the neuroticism score was significantly
associated with LLD2 [β=-1.09x10^{-2}±2.42x10^{-3}, -$\log_{10}$(P-value)=5.20] (**Supplementary eFile 3**).
A previous study suggests distinct neural mechanisms between older individuals with neurotic
and non-neurotic depression, indicating diverse biological pathologies contributing to varying
clinical presentations of LLD[33].
We conducted two sensitivity analyses to validate the main PWAS results. We obtained
high concordance rates in split-sample (98.03%) and sex-stratified analyses (93.98%). Detailed
results can be found in **Supplementary eText 1** and **Supplementary eFile 4** and **5** for split-
sample and sex-stratified analyses.
As anticipated, 91% of the significant associations were linked to the brain, given that the
DNEs were derived from regional brain volumetrics in brain disease-specific populations.
However, it is noteworthy that these phenotypic associations extended beyond the brain,
providing evidence for the significant associations between the brain and other organ systems.
This brain-body connection was consistent with previous literature on multi-organ research using
imaging and genetic data[17,34,35].

Figure 2: **Phenome-wide associations of the nine DNEs**

226
a) The neuroanatomical patterns of the nine DNEs were manifested in the UKBB general
population and were concordant with the patterns initially derived from the original disease
populations[1–4]. A linear regression model was applied to the 119 gray matter regions of interest
(ROIs) derived from T1-weighted MRI data while accounting for various covariates (**Method**
3b). We present the β coefficients of the ROIs that withstood the Bonferroni correction. Positive

correlations are depicted using warm reddish colors, while cold blue colors represent negative
correlations. For AD2, we showed the sagittal view to visualize the hippocampus and medial
temporal lobe. **b)** The nine DNEs are over-expressed (i.e., a higher mean of the DNE score in the
population) and under-expressed (i.e., a lower mean of the DNE score) in the general population
compared to the disease populations. The kernel density estimates of the nine DNEs are shown
for both the training dataset (gray-colored in patients) and the independent test dataset from the
UK Biobank (UKBB). Significant differences that survived the Bonferroni corrections between
the training and independent test datasets (two-sampled t-test) are denoted with the symbol *. **c)**
Phenome-wide associations (PWAS) between the nine DNEs (left panel) and 611 phenotypes
(middle panel) are dominated by brain phenotypic measures. The right panel shows
representative phenotypes linked to multiple phenotype categories with the highest statistical
significance after the Bonferroni correction (P-value<0.05/611). A thicker colored line
corresponds to a higher value of -log10(P-value). The symbols "+" and "-" represent positive and
negative correlations. IDP: imaging-derived phenotype; OD: orientation dispersion; FA:
fractional anisotropy; ICVF: intracellular volume fraction; FC: functional connectivity; DSST:
digit symbol substitution test.
248
Genome-wide associations identify 66 genomic loci associated with the nine DNEs

At the genome-wide significance level (P-value<5×10^{-8}), GWAS using PLINK for a linear
regression model (**Method 4a**) identified 10, 8, 5, 21, 9, 1, 3, 3, and 6 genomic loci significantly
associated with AD1, AD2, ASD1, ASD2, ASD3, LLD1, LLD2, SCZ1, and SCZ2, respectively
(66 in total, **Fig. 3a,** and **Supplementary eFile 6**). At a more stringent significance level (P-
value<$5 \times 10^{-8}/9$), 31 loci passed the Bonferroni correction. Notably, 4 loci linked to LLD1-2 and
SCZ1 are new – their top lead SNP was not associated with any clinical traits in the EMBL-EBI
GWAS Catalog[36] and not presented in **Fig. 3b** for our phenome-wide query, as annotated in **Fig.**
3a (Method 4c, query date: 2nd June 2023, via FUMA version: v1.5.4**)**. To support the
robustness of our GWAS, we estimated the intercept of linkage disequilibrium score regression
(LDSC)[37] and obtained intercepts of 0.9997±0.0093, 1.0325±0.0091, 0.9962±0.0095,
1.0172±0.0099, 1.0117±0.0085, 1.0135±0.008, 1.0162±0.0094, 1.0101±0.0087, and
1.0124±0.0095 for the nine DNEs. All intercepts were close to 1, indicating no substantial
genomic inflation in our GWASs. The Manhattan and QQ plots of the nine GWASs are
presented in **Supplementary eFigure 1-9** and are also publicly available on the MEDICINE
knowledge portal: https://labs-laboratory.com/medicine/.
All DNEs are significantly heritable ($0.24 < h^2 < 0.66$, P-value<1×10^{-10}) after Bonferroni
correction (**Fig. 3a**, **Supplementary eTable 2**, and **Method 4b**). We employed the GCTA[38]
software to estimate h^2, acknowledging that previous research has demonstrated variations in the
magnitude of h^2 estimates based on the choice of methods. The h^2 estimates obtained through
GCTA or similar methods may underestimate SNP-based heritability (i.e., missing heritability),
potentially due to unaccounted factors such as gene-environment interactions, epistasis, and rare
variant effects.
We further investigated the significant genomic loci by mapping them to protein-
encoding genes and examining their functional implications through expression quantitative trait
loci (eQTL) mapping. **Supplementary eFigure 10** presents the regional Manhattan plot for the
most significant genomic locus associated with each DNE. For example, we identified a locus
associated with ASD2 (top lead SNP: rs3068507 at 20q11.21) and a neighboring locus associated
with SCZ1 (top lead SNP: rs6088962 at 20q11.21), both of which mapped to the *MYLK2* gene

(**Supplementary eFigure 10d** and **h**). *MYLK2* encodes a myosin light chain kinase primarily
expressed in adult skeletal muscle.
We conducted seven sensitivity analyses to validate the main GWAS results (**Method**
4a). We obtained perfect concordant rates (100%) and similar genomic inflation factors using
fastGWA[39,40] for a generalized linear mixed model in the nine GWAS. Specifically, we excluded
the related individuals (up to 2nd-degree) in our genetic quality check pipeline; mixed effect
models like fastGWA can detect additional genetic relatedness without excluding individuals by
using a sparse genomic relationship matrix, significantly reducing the computational burden for
large-scale GWAS. This sensitivity check further supports that no substantial genomic inflation
exists in our main GWASs. We also observed high concordance rates in split-sample, sex-
stratified (63.26-92.54%), and longitudinal GWAS analyses (100%, *N*=1116), but the
concordance rates were relatively low in non-European ancestry GWAS, independent ADNI
whole-genome sequencing GWAS, and six case-control GWAS[41–46] of neurodegenerative and
neuropsychiatric disorders from the Psychiatric Genomics Consortium (PGC)[47] (**Supplementary**
eTable 3a). The sample sizes for the non-European (*N*=4783) and ADNI (*N*=1555) samples are
small; the case-control GWAS from the PGC may overlook the heterogeneity within each
disease. Detailed results are presented in **Supplementary eText 2** for the sensitivity results,
Supplementary eFile 7-13 for replicated SNPs/loci, and **Supplementary eFigure 1-9** for
Manhattan and QQ plots and the LDSC intercepts. In conclusion, our GWASs were robust across
several scenarios and identified 4 new genomic loci that previous case-control GWASs might
have missed.
299
The genetic associations of the nine DNEs parallel their phenotypic associations

We performed a phenome-wide look-up analysis (**Method 4d**) to understand the phenotypic
associations in the literature for the identified genomic loci in our GWAS.
In total, 2525 clinical traits were associated with genetic variants in our GWAS,
including traits linked to multiple organ systems, cognition, and lifestyle factors (**Fig. 3b** and
Supplementary eFile 14). The genomic loci were largely associated with clinical traits of the
brain (53%), musculoskeletal (17%), immune system (6%), neurodegenerative (1%), and
neuropsychiatric (1%) diseases. For example, AD2 genomic loci were largely associated with
traits related to the brain (565 out of 781, e.g., brain IDPs), musculoskeletal (133/781, e.g.,
standing height), immune (17/781, e.g., reticulocyte count), cognition (15/781, e.g., cognitive
performance), lifestyle factors (13/781, e.g., smoking), and neurodegenerative traits (1/781, i.e.,
neurofibrillary tangles).
The findings closely align with the phenotypic associations observed in **Fig. 2c**,
reinforcing that the DNEs share genetic determinants linked to organs beyond the brain, lifestyle
factors, and cognition.

Figure 3: **Genome-wide associations of the nine DNEs**

316
a) Genome-wide associations identified 66 (10, 8, 5, 21, 9, 1, 3, 3, 6 for the nine DNEs) genomic
loci (P-value<5x10^{-8}) associated with the nine DNEs. Using the top lead SNP, we denoted each
genomic loci linked to the 9 DNEs. Red * symbols indicate that the locus (considering the top

lead SNP and SNPs in high LD with it) have not been previously associated with any trait in the
EMBL-EBI GWAS catalog. The left legend indicates the significant SNP-based heritability (h^2)
for the nine DNEs; the right legend represents the SNP density of our genetic data throughout the
human genome. GWAS was performed using the Genome Reference Consortium Human Build
37 (GRCh37). **b**) Phenome-wide association query of the previously identified genomic loci (left
panel) in the EMBL-EBI GWAS Catalog (via FUMA 1.4.2) shows a brain-dominant genetic
architecture. We categorized all clinical traits (middle panel) into several high-level categories
linked to multiple organ systems, neurodegenerative and neuropsychiatric disorders, lifestyle
factors, etc. We then show the keyword cloud plots for each category (right panel).
329
The genetic correlation of the nine DNEs

To understand the shared genetic underpinnings, we estimated the genetic correlation[37] (g_c)
(**Method 4e**) between the nine DNEs, the BAG of nine human organ systems[17], and six brain
diseases (AD, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar,
obsessive-compulsive disorder, schizophrenia; **Supplementary eTable 3a**) from PGC and four
lifestyle factors and cognitive scores (**Supplementary eTable 3b**).
We first estimated the g_c between each pair of DNEs (**Fig. 4a**). Numerous DNEs
exhibited strong genetic correlations among each other. The highest positive genetic correlation
was obtained between ASD2 and SCZ1 (g_c=0.57±0.04); the highest negative genetic correlations
were obtained between ASD2 and ASD1 (g_c=-0.55±0.04), and between ASD3 and SCZ1 (g_c=-
0.51±0.05). We also observed a substantial alignment between the phenotypic correlation (p_c)
and the genetic correlation of pairwise DNEs, supporting the long-standing Cheverud's
Conjecture[48]. However, we identified two exceptions where the observed phenotypic and genetic
correlations exhibited opposite directions. ASD1 and ASD3 showed a negative phenotypic (p_c=-
0.39±0.08) but a positive genetic correlation (g_c=0.21±0.05); ASD1 and LLD1 showed a
negative phenotypic (p_c=-0.34±0.09) but a positive genetic correlation (g_c=0.16±0.07)
(**Supplementary eTable 4**). This implies that non-genetic factors, such as lifestyle and
environmental factors, may exert opposite influences on the two DNEs. We performed additional
MAGMA gene-set analysis[49] to test the genetic similarity between ASD2 and SCZ1. The most
significant biological pathway underlying ASD2 is the negative regulation of locomotion (GO
0040013, P-value=2.27x10^{-5}, β=0.22±0.02), implicated in biological processes that stop, prevent,
or reduce the frequency, rate, or extent of locomotion of a cell or organism. The most significant
biological pathway for SCZ1 is the negative regulation of neurotransmitter transport (GO
0051589, P-value=1.41x10^{-5}, β=0.22±0.02), involved in biological processes that downregulate
the directed movement of a neurotransmitter into, out of, or within a cell. In particular, the latter
supports the involvement of dopamine and glutamate, two major neurotransmitters in the central
nervous system, in schizophrenia[50].
Between the nine DNEs and the BAGs across nine human organ systems, we found
significant genetic correlations between AD1 (g_c=0.23±0.05), ASD1 (g_c=0.44±0.05), LLD2
(g_c=0.24±0.07), SCZ1 (g_c=0.26±0.06), and the brain BAG, and between ASD1 and the eye BAG
(g_c=0.19±0.07) (**Fig. 4b** and **Supplementary eTable 5**).
Finally, we also found a marginally significant genetic correlation between AD2 and AD
(g_c=0.22±0.12), AD1 and bipolar disorder (BIP, g_c=-0.08±0.04), and ASD3 and BIP
(g_c=0.09±0.04) using GWAS summary statistics from PGC (**Fig. 4c** and **Supplementary eTable
6a**). We observed a nominal genetic correlation signal between ASD1 and reaction time
(g_c=0.35±0.15; **Fig. 4d** and **Supplementary eTable 6b**).

In summary, the nine DNEs demonstrate substantial genetic correlations among
themselves and with organ systems beyond the brain. These findings highlight the
interconnectedness of the neuroanatomical patterns and genetic determinants across multiple
body systems and diseases, suggesting shared underlying disease mechanisms and potential
pleiotropic effects.
371
The genetic colocalization of the nine DNEs

To seek the shared causal variants between two clinical traits (e.g., AD1 vs. LLD2), we
performed Approximate Bayes Factor colocalization[51] analyses (**Method 4f**) between the nine
DNEs (**Fig. 4e**), with the nine BAGs (**Fig. 4f**), and the six brain disorders from PGC[47] (**Fig. 4g**).
Among the nine DNEs, we detected 44 causal variants (SNPs) exhibiting significant
colocalization signals. We showcased the shared causal variant (rs2790099 at 6p21.1) between
ASD2 and SCZ2 with a PP.H4.ABF (Approximate Bayes Factor)=0.92 (**Fig. 4e**), which
examines the posterior probability (PP) to evaluate the hypothesis, the presence of a single
shared causal variant associated with both traits within a specific genomic locus. This causal
SNP was mapped to the *RUNX2* gene. The loss of function in *RUNX2* causes a rare autosomal
dominant skeletal disorder – cleidocranial dysplasia[52], but it was implicated in ASD or SCZ in
previous literature.
Between the nine DNEs and nine BAGs, we identified 13 causal variants (SNPs)
exhibiting significant colocalization signals. We showcased the shared causal variant (rs5848503
at 3p22.1) between ASD2 and the brain BAG with a PP.H4.ABF=0.95 (**Fig. 4f**). One mapped
gene in this locus is the *MOPB* gene, which encodes the myelin-associated oligodendrocytes
basic protein and is actively involved in the structural constituent of the myelin sheath and
nervous system development. This gene was previously implicated in ASD using single-cell
genomics[53], SCZ[54], amyotrophic lateral sclerosis, and Parkinson's disease[55].
Between the nine DNEs and six brain diseases from PGC, we identified 6 causal variants
(SNPs) exhibiting significant colocalization signals. We showcased the shared causal variant
(rs9257566 at 6p22.1) between ASD3 and SCZ with a PP.H4.ABF=0.82 (**Fig. 4g**). In this locus,
multiple olfactory receptor (OR) genes and the dysfunction of the olfactory system were
implicated in SCZ[56,57] and ASD[58,59]. For instance, the *OR2J2* and *OR2J3* genes are two protein-
coding genes in copy number variants associated with SCZ using microRNA data[60]. The causal
SNP (rs9257566) was associated with SCZ and brain IDP, such as white matter microstructural
measures (**Supplementary eFigure 11**). Besides those two conditions, AD has also been widely
associated with early olfactory dysfunction[61,62]. The sensitivity checks on the prior probability
(*p12*) for the three illustrations are shown in **Supplementary eFigure 12a-c**. The causal variant,
cytogenetic region, and their colocation signal direction (based on β coefficients) are presented in
Supplementary eFigure 13a-c. Detailed results are shown in **Supplementary eFile 15-17**.
The genetic colocalization of the nine DNEs revealed causal genetic variants, indicating
that the same genomic regions may causally influence the expression of these AI-derived
endophenotypes.
406
407 **The causal relationship of the nine DNEs**

408 We applied bidirectional two-sample Mendelian randomization analyses[63] (**Method 4g**) to depict
409 a causal network between the nine DNEs, the eight BAGs (excluding the brain BAG), and eleven
410 chronic diseases spanning the whole-body system.

411   For each pair of DNEs, as the GWAS populations completely overlapped, conducting
412 two-sample Mendelian randomization was not feasible[64]. Alternatively, the split-sample GWAS
413 did not yield sufficient statistical power due to the limited number of instrumental variables (VI)
414 available (< 6 SNPs).
415   Among the nine DNEs and eight BAGs, we found potential causal effects of the eye
416 BAG on LLD1 [P-value=$4.57\text{x}10^{-3}$, OR (95% CI) = 1.14 (1.04, 1.24), number of SNPs=16], the
417 cardiovascular BAG on ASD3 [P-value=$6.04\text{x}10^{-3}$, OR (95% CI) = 1.16 (1.04, 1.29), number of
418 SNPs=34], and the pulmonary BAG on LLD2 [P-value=$1.98\text{x}10^{-3}$, OR (95% CI) = 1.14 (1.04,
419 1.25), number of SNPs=49]. No significant causal signals persisted after the Benjamini-
420 Hochberg correction in the inverse analyses (**Fig. 4h**). Details of the results, including all five
421 different Mendelian randomization estimators, are shown in **Supplementary eFile 18**.
422   Between the nine DNEs and eleven chronic diseases, encompassing brain-related
423 conditions and diseases affecting other organs, we identified a potential causal effect from AD2
424 to AD using the GWAS summary statistics from PGC – the largest sample size (N=1,126,536
425 individuals) in the AD case-control study [P-value=$1.74\text{x}10^{-4}$, OR (95% CI) = 1.25 (1.11, 1.40),
426 number of SNPs=7] (**Fig. 4i**). We didn't detect a causal link in the opposite direction from AD to
427 AD2. This aligns with the endophenotype hypothesis, suggesting that DNEs are situated within
428 the causal pathway from genetics to external phenotypes, such as AD diagnosis and cognitive
429 decline. Details of the results, including all five different Mendelian randomization estimators,
430 are shown in **Supplementary eFile 19**. The results of the sensitivity check are presented in
431 **Supplementary eFigure 14-17**.
432   The Mendelian randomization results further emphasize the potential benefits of overall
433 organ health for brain-related conditions. This highlights the interconnectedness between various
434 organ systems and the brain, underscoring the significance of a holistic health and disease
435 prevention approach.

 Figure 4: **The genetic correlation, colocalization, and causal networks of the nine DNEs**

437
a) The genetic correlation between two DNEs (g_c, lower triangle) mirrors their phenotypic
correlation (p_c, upper triangle). Red-shadowed rectangles highlight two exceptions. The symbol
* indicates significant results after the Benjamini-Hochberg correction. The symbol # indicates
nominal significance. **b**) genetic correlations between the nine DNEs and nine biological age

gaps (BAG) for nine human organ systems[17]. **c**) genetic correlations between the nine DNEs and
six neurodegenerative and neuropsychiatric disorders. **d**) genetic correlations between the nine
DNEs and four traits related to lifestyle factors and cognition. **e**) genetic colocalization was
evidenced at one locus (6p21.1) between ASD2 and SCZ1. The signed PP.H4.ABF (0.92)
denotes the posterior probability (PP) of hypothesis H4, which suggests that both traits share the
same causal SNP (rs2790099). A positive PP indicates concordant β values for both DNEs, while
a negative PP implies opposite β values. **f**) genetic colocalization was evidenced at one locus
(3p.22.1) between ASD2 and brain BAG: PP.H4.ABF=0.95 with the cause SNP rs5848503. **g**)
genetic colocalization was evidenced at one locus (6p.22.1) between ASD3 and SCZ case-
control GWAS[45] from PGC (European ancestry): PP.H4.ABF=0.82 with the cause SNP
rs9257566. **h**) the causal network of the nine DNEs with the eight multi-organ BAGs. Solid
arrow lines (from the exposure to the outcome variables) indicate significant causal relationships
after the Benjamini-Hochberg correction; dotted arrow lines show nominal significance (P-
value<0.05). The symbols + (OR>1 and g_c>0) and – (OR<1 and g_c<0) represent a positive
relationship between the two traits. **i**) the causal network of the nine DNEs with the eleven
chronic diseases (e.g., AD, ADHD, BIP, and SCZ from PGC). Abbreviation: AD: Alzheimer's
disease; ADHD: Attention-deficit/hyperactivity disorder; ASD: autism spectrum disorder; BIP:
bipolar disorder; SCZ: schizophrenia; OCD: Obsessive-compulsive disorder; RA: rheumatoid
arthritis; CD: Crohn's disease; T2D: type 2 diabetes; IBD: inflammatory bowel disease; PBC:
Primary biliary cirrhosis.
462
The nine DNEs and their PRSs significantly improve prediction for 14 systemic diseases
and mortality
We investigated the added prediction power of the nine DNEs and their respective PRS (**Method**
4h) for 14 systemic diseases based on the ICD-10 code (**Supplementary eTable 7-8**), 8
cognitive scores(**Supplementary eTable 9**), and mortality outcomes (i.e., the date of death). The
definition of the patient and healthy control groups and the mortality outcome are presented in
Method 5. Of note, we did not perform prediction on the four brain diseases (AD, ASD, LLD,
and SCZ) due to the small and highly imbalanced sample sizes in the UKBB general population
(**Method 1**). As anticipated, the prediction performance across all tasks was modest, considering
that the DNEs were derived from specific disease populations.
In addition to commonly available features, such as age and sex, we found that AD1,
ASD1, LLD1, SCZ1, and SCZ2 provided additional prediction power (i.e., incremental R^2) for
many disease categories (**Method 5a**). Across the 14 disease categories, the DNEs showed
higher incremental R^2 in mental and behavioral disorders (ICD-10 code: F group) and diseases
linked to the central nervous system (ICD-10 code: G group) than other disease categories,
proving that the nine DNEs in the general population capture disease-related effects of the four
brain diseases. Combining all nine DNEs further improved the incremental R^2, especially in
mental and behavioral disorders (R^2=1.01%, P-value=1.74x10^{-5}) and diseases linked to the
central nervous system (R^2=0.63%, P-value=1.33x10^{-5}) (**Fig. 5a**). The incremental R^2 values for
all tests are shown in **Supplementary eTable 7**. All metrics, encompassing sample sizes and
incremental R2 for both the null and alternative models, are outlined in **Supplementary eFile**
20. Results using only the PRS target population are presented in **Supplementary eFigure 18**.
Compared to the nine DNEs, the nine PRSs provided smaller additional prediction power.
For example, the PRS for ASD3 explained an additional 0.05% of the variance (incremental R^2)

in diseases associated with the blood and immune systems (P-value=0.03), as well as neoplasms (P-value=0.04). Combining all nine PRSs improves the incremental R^2, particularly in mental and behavioral disorders (R^2=0.3%, P-value=0.047). No results survived multiple comparisons using the Benjamini-Hochberg method (**Fig. 5b**). Detailed results are shown in **Supplementary eTable 8** and **eFile 21**.

We assessed the prediction ability of support vector machines (SVM) at the individual level to classify the 14 disease categories (**Method 5b**). The highest performance was observed for eye diseases (ICD-codes: H0-5). Age and sex significantly enhanced the classification accuracy. Including age and sex alongside the 9 DNEs and 9 PRSs boosted the classification accuracy from 0.55 to 0.65. The inclusion of PRSs, DNEs, and the combination of both, along with age and sex as features, resulted in improved classification accuracy for mental and behavioral disorders. For example, the accuracy increased from 0.51 to 0.55 and 0.57 for features of age and sex, 9 DNEs, and 9 PRSs, incrementally (**Fig. 5c**). These findings highlight the added value of incorporating the nine DNEs and PRSs in predicting these disease categories. Detailed results are shown in **Supplementary eTable 9a**. The full evaluation metrics of the cross-validated and independent test results are presented in **Supplementary eFile 22**.

We examined the predictive capability of these feature sets in estimating 8 cognitive scores (**Method 5c**). The digit symbol substitution test (DSST) demonstrated the highest performance, reaching a Pearson's r of 0.46 (e.g., P-value=3.9×10^{-189} and MAE=3.75 for the feature set of 9 DNE plus covariates) in the independent test dataset using all different sets of features (**Fig. 5d**). The combination of DNEs and PRSs did not notably enhance prediction accuracy. However, contrary to the 14 systemic disease classifications, incorporating the 119 GM imaging-derived phenotypes alongside DNEs and PRSs resulted in a 2% increase in the prediction accuracy for fluid intelligence, measured by Pearson's r (**Supplementary eTable 9b**). The full evaluation metrics of the cross-validated and independent test results are presented in **Supplementary eFile 23.**

Finally, we evaluated the prediction power of the nine DNEs and PRSs for mortality risk prediction using the Cox regression (**Method 5d**). Among these, SCZ1, SCZ1-PRS, ASD1, and AD1-PRS were significantly associated with the risk of mortality (**Fig. 5e** and **Supplementary eTable 10a**). Adding SCZ1, AD1-PRS, ASD1, and SCZ1-PRS to age and sex further improved the prediction, but the performance decreased afterward (**Fig. 5f**). Lastly, incorporating the nine DNEs from the second scan of 1348 participants into the model slightly increased the statistical significance and the HR (**Supplementary eTable 10b** and **c**)

Figure 5: **Additional prediction power of the nine DNEs and PRSs for 14 systemic diseases,**
cognition, and mortality outcomes

a) The incremental R-squared (R^2) values of the nine DNEs for predicting 14 systemic disease
categories were assessed using the entire UKBB sample, with N=39,178 participants as
independent test data. The results focusing only on the PRS target population (N=15,891) can be
found in **Supplementary eFigure 18**. "ALL" indicates the incremental R^2 contributed by

combining the nine DNEs. **b**) The incremental R^2 of the PRS of the nine DNEs to predict 14
systemic diseases based on the ICD-10 code using only the PRS target sample. **c**) In the PRS
target sample, disease classification accuracy from the independently hold-out test data (N=5581)
was assessed using nested cross-validated support vector machines in the training/validation/test
data (N=10,000) by fitting various sets of features (Cov indicates age and sex). **d**) In the PRS
target sample, cognitive score prediction accuracy (Peasrson's r) from the independently hold-out
test data (3632<N<5570) was assessed using nested cross-validated support vector regression
models. **e**) The SCZ1, SCZ1-PRS, AD1-PRS, and ASD1 show significant associations with the
risk of mortality in the PRS target sample. Age and sex were included as covariates in the Cox
proportional hazard model. **f**) The nine DNEs and PRSs were cumulatively included as features
in cross-validation for mortality risk prediction. The symbol * indicates significant results that
survived the Benjamini-Hochberg correction. The symbol **#** indicates nominal significance. HR:
hazard ratio; CI: concordance index; DSST: digit symbol substitution test; TMT: trail-making
test.

Discussion

This study investigated the manifestation of nine disease-related brain endophenotypes – derived from four case-control studies via semi-supervised AI methods – in the general population of 39,178 participants in UKBB. We assessed commonalities and differences among the nine DNEs, their genetic correlates in the general population, their relationships with the multiple human organ systems, and their predictive capacity for 14 systemic disease categories and mortality. Our findings demonstrate the potential of the nine AI-derived DNEs in identifying high-risk individuals within the general population prone to developing the four major brain disorders.

Shared neuroanatomical patterns and genetic determinants across the four brain diseases

in the general population

Understanding the shared disease mechanism of neurodegenerative and neuropsychiatric diseases is a complex and ongoing challenge in medical research[15,16,41,43–46,65]. Our results suggest that shared underlying mechanisms and genetic factors may contribute to the development and progression of these disorders. This notion of shared disease mechanisms across the four major neurodegenerative and neuropsychiatric diseases, namely ASD, SCZ, LLD, and AD, has garnered considerable attention and reshaped our understanding of these conditions[15,16].

Despite the inherent heterogeneity among neuroanatomical patterns observed in different brain diseases (**Fig. 2a**), a notable commonality exists regarding their manifestations, which might emanate from underlying mechanisms sharing neuropathologic characteristics and pathways. As an illustration, AD1, LLD2, and SCZ1 exhibited a negative correlation (brain atrophy) with widespread cortical volumes, such as the bilateral insula and middle frontal gyrus. This aligns with expectations, considering that the UKBB population includes individuals primarily from mid to late life (above 45 years). From an etiological standpoint, various factors can contribute to the global cortical volume reduction within the general population, with late-onset neurodegenerative and neuropsychiatric disorders and aging exerting a significant impact. Likewise, ASD2 and SCZ2 exhibited a positive association with the basal ganglia, including the globus pallidum. This could imply the existence of potential protective genetic or environmental factors that collectively contribute to the concept of "brain reserve", which might mitigate volume loss in a portion of the general population. Notably, we previously revealed that individuals predominantly expressing SCZ2 exhibited higher levels of education[4] and higher remission rates than those primarily influenced by SCZ1. Alternatively, these volume increases might reflect neuropathologic mechanisms, such as disrupted connectivity, which are not necessarily associated with neurodegenerative and neurodevelopmental components related to relatively lower brain volumes. Ultimately, another significant aspect to consider involves the impact of medications prescribed by clinicians, affecting both disease-specific and general populations. Research indicates that antipsychotic medications, commonly prescribed for most individuals with schizophrenia and some with ASD and AD, have been shown to delay brain volume loss in the basal ganglia[66] and pallidum[67].

The commonalities in neuroanatomical patterns across brain diseases can be attributed to several factors. First, shared genetic factors may influence brain structure and function[28,30], contributing to similar neuroanatomical alterations across different diseases. Genetically, this was largely evidenced by our genetic correlation (**Fig. 4a**) and colocalization results (**Fig. 4e**).

For instance, ASD2 showed prominent positive genetic overlap with SCZ1. Historically, there has been a long-standing association between ASD and SCZ, leading to the notion that autism could be a form of "childhood schizophrenia"[68]. This conceptual link between the two conditions has been debated and discussed. Previous case-control neuroimaging studies demonstrated divergent structural and functional brain patterns in individuals with ASD compared to those with SCZ[69,70], largely ignoring the neuroanatomical heterogeneity within each condition. Genetic variants that impact key signaling pathways, synaptic function, and neuronal connectivity[71,72] could influence multiple disease phenotypes, leading to overlapping neuroanatomical patterns.

AD1 also shared genetic similarities with LLD1, both characterized by spatially extensive brain atrophy and increased brain age. Previous studies found a higher prevalence of depressive symptoms and LLD in individuals with AD compared to the general population[73–75]. The relationship between AD and LLD likely involves multiple factors and may be bidirectional. On the one hand, LLD may increase the risk of developing AD or accelerate the progression of cognitive decline in individuals already affected by AD. On the other hand, AD-related changes in the brain, such as neuroinflammation and neurochemical imbalances, may worsen depressive symptoms in individuals with LLD.

Recognizing the shared disease mechanisms across the four brain diseases underscores the importance of a broader perspective on clinical presentations and underlying biological mechanisms. This understanding is important for developing targeted and personalized approaches to patient care, leading to more effective treatments and interventions. Future research may explore disease heterogeneity to transcend traditional classification boundaries and identify data-driven subtypes or dimensions within a transdiagnostic framework[76].

Beyond the brain

Our findings strongly concur with a paradigm shift in treating brain diseases. While the conventional approach has predominantly concentrated on interventions targeting the brain, emerging evidence highlights the critical importance of considering the broader systemic and environmental factors that influence disease onset and progression.

Unraveling the intricate interconnections between the brain and other organ systems is crucial in broadening our understanding of brain diseases, as demonstrated by our findings and other findings. The brain does not function in isolation but interacts with and is influenced by various physiological systems throughout the body. Our results showed a close genetic association and causality between the DNEs and the eye, cardiovascular, and pulmonary systems (**Fig. 4b**, **f**, and **h**). These findings parallel previous literature. For instance, eye-related pathological changes have been revealed to mirror early signs of neurological and neuropsychiatric conditions[77]. The nervous and cardiovascular systems – the heart-brain axis – are intricately linked, with brain regions controlling heart function via sympathetic and parasympathetic pathways[78]. Dysfunctions in one system can affect the other's function, resulting in brain and cardiovascular diseases. The immune system plays a crucial role in modulating inflammation and neuroinflammation, which are implicated in many brain disorders, such as AD[79], SCZ[80], and depression[81]. Similarly, the gut-brain axis highlights the bidirectional communication between the gut microbiota and the brain, with emerging evidence linking alterations in the gut microbiome to brain diseases such as Parkinson's disease[82] and depression[83]. Understanding and targeting these systemic interactions can modulate disease processes and improve treatment outcomes.

Furthermore, considering environmental and lifestyle factors is essential in treating brain
diseases[84]. Our previous work[17] has shown that the BAGs of nine human organ systems comply
with Cheverud's Conjecture: the phenotypic correlation of two BAGs mirrors their genetic
correlations. However, herein we showed that the phenotypic correlation between two DNEs
(e.g., ASD1 vs. LLD1) did not reflect their underlying genetic correlation (**Fig. 4a**), indicating
potentially strong environmental and lifestyle factors that exert opposite effects on the two
DNEs. Furthermore, an interesting observation from our study was that the heritability estimate
(h^2) of early-onset diseases, such as ASD, was higher than that of late-onset diseases, such as
LLD, within the three neuropsychiatric disorders. This finding suggests that genetic factors play
a more prominent role in developing ASD at a younger age. In contrast, other factors, such as
environmental influences, socioeconomic factors, and lifestyle choices, may have a stronger
impact on developing LLD later in life. These differential heritability patterns shed light on the
complex interplay between genetic and non-genetic factors in the underlying disease mechanism
of neurodegenerative and neuropsychiatric disorders across different stages of life. These
heritability patterns aligned with a previous study that examined multiple GWAS drawn from
more than 200,000 patients for 25 brain-associated disorders and 17 phenotypes[16].
In conclusion, going beyond the brain is crucial for understanding and treating brain
diseases. By considering the connections between the brain and other organ systems,
understanding the impact of environmental and lifestyle factors, and harnessing the power of
advanced AI technologies, we can develop more effective and personalized approaches to
prevent, diagnose, and treat brain diseases.
652
653 AI-derived DNEs for precision diagnostics in the general population

The present study leverages cutting-edge, semi-supervised AI methods[22] and open science
advancements to enhance our understanding of disease heterogeneity in neurodegenerative and
neuropsychiatric disorders[1–3,6,9]. In this context, implementing these AI-derived DNEs at early
disease or preclinical stages – in the general population – may facilitate the identification of
individuals at risk, and the initiation of proactive interventions before the onset of noticeable
symptoms, likely leading to more effective treatments and interventions and better outcomes.
The proposed AI-derived DNEs capture intricate brain structure and function variations,
often subtle and spatially complex, which traditional diagnostic methods and case-control studies
may overlook. By quantifying the neuroanatomical patterns associated with specific brain
disorders, DNEs may offer a personalized disease vulnerability assessment, inform interventions
at early preclinical stages, and potentially prevent or delay the onset of symptoms. At the
individual level, integrating genetic information (i.e., PRSs) with DNEs significantly improves
prediction performance for 14 systemic diseases and mortality outcomes (**Fig. 5**). In addition, our
Mendelian randomization analyses supported the well-established endophenotype hypothesis in
genetic psychiatry[23] – endophenotype in psychiatric disorders resides inside the causal pathway
from underlying genetics to their exo-phenotypes (i.e., the disease syndrome itself), thereby
being closer to its disease mechanisms. We found that AD2, characterized by focal medial
temporal lobe atrophy, exerted a causal relationship with AD. However, we did not find evidence
of a reverse causal relationship, suggesting that the underlying genetics may influence the
development of AD through the DNE, although it may not be the exclusive pathway contributing
to the disease. This highlights the role of genetics in influencing the disease process, particularly
through the identified DNE, shedding light on potential pathways and mechanisms involved in
AD development.

677
Limitation

The present study has several limitations. Firstly, the genetic analysis focused exclusively on
common genetic variants. Future investigations should explore the contribution of rare variants
to these brain diseases. Secondly, it is important to recognize that our GWAS analyses
predominantly involved participants of European ancestry, limiting the generalizability of the
genetic findings to other populations with different ancestral backgrounds. Further research
efforts are necessary to collect more diverse genetic data and include underrepresented racial and
ethnic groups to enhance the generalizability of the findings. Additionally, the validation of the
nine DNEs would benefit from additional longitudinal analyses. Fortunately, ongoing efforts to
collect longitudinal brain MRI data in UKBB[85] hold promise for providing valuable insights to
the scientific community and advancing the field of precision medicine. Furthermore, more
advanced methodological developments will be developed and integrated within our semi-
supervised clustering learning framework to alleviate potential domain shifts[86]. Finally, our
future research will incorporate multimodal imaging to generate DNEs sensitive to a broader
range of brain alterations, including macrostructural volumetric changes, functional disruptions,
and structural network abnormalities.
694
Outlook

696 Together, our AI-derived DNEs have emerged as novel instruments for precision medicine. By
697 capturing the complexity and heterogeneity of brain disorders, DNEs provide a better
698 understanding of disease pathology, facilitate personalized risk assessment, and hold promise for
699 targeted interventions and population selection.

Methods

Method 1: Study populations

Our previous studies used semi-supervised AI models to define the nine DNEs from four disease case-control populations. These populations consisted of 865 healthy controls (CN), 1096 individuals with mild cognitive impairment (MCI), and 414 AD patients from ADNI[20] for AD1 and AD2, 362 typically developing controls, and 307 patients with autism spectrum disorder (ASD) from ABIDE[21] for ASD1-3, 495 healthy controls and 501 LLD patients from the LLD study[3] for LLD1-2, and 364 healthy controls and 307 SCZ patients from PHENOM[4] for SCZ1-2. For more detailed information about the characteristics of the study populations, please refer to the original papers.

The trained AI models were then applied to the UKBB general population as independent data. UKBB is a population-based study of approximately 500,000 people recruited from the United Kingdom between 2006 and 2010. The UKBB study has ethical approval, and the ethics committee is detailed here: https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/governance/ethics-advisory-committee. The current study analyzed 39,178 multimodal brain MRI data from UKBB. T1-weighted MRI data were locally processed at the University of Pennsylvania; imaging-derived phenotypes (IDP) from diffusion and resting-state functional MRI were downloaded from UKBB. In addition, we processed the imputed genotype data[26] from UKBB for GWAS analyses. Last, other clinical traits were also analyzed, including phenotypes related to nine human organ systems. The current work was performed under application numbers 35148 and 60698. To unbiasedly evaluate the PRS and machine learning models, we defined the following populations:

- *Disease case-control populations*: The four datasets used to train the AI models and define the nine DNEs from four brain diseases.
- *Independent UKBB general population (N=39,178)*: The UKBB population in which the trained AI models were applied to derive the nine DNEs.
- *PRS base/target population (split1/split2) (N=15,968)*: the UKBB population was divided into two splits (split1 vs. split2) in the split-sample GWAS. To derive the PRS, we used the GWAS from split1 as the base data and split2 as the target data. All disease and mortality prediction tasks involving PRS used only the PRS target population (*N=15,968*).

Within the UKBB general population, individuals with various diseases are classified under the ICD-10 code (Data field: 41270), though often in smaller numbers. Among the 39,178 participants from the UK Biobank included in our study, we outline the sample sizes and criteria for the healthy control group, as well as those with AD, ASD, LLD (encompassing a broad spectrum of depression), and SCZ, all categorized according to the ICD-10 code:

- *Healthy control*: 6390 participants without any ICD-10-based disease diagnoses from the data field: 41270 from the training/validation/test dataset in **Method 5**.
- *AD*: 23 AD patients based on the ICD-10 code (G30).
- *ASD*: 6 ASD patients based on the ICD-10 code (F84.0).
- *LLD*: 1329 patients based on the ICD-10 code (F32).
- *SCZ*: 23 SCZ patients based on the ICD-10 code (F20).
- *The 14 systemic disease categories*: we used the ICD-10 code to define the disease groups. The exact ICD-10 code for each category is detailed in **Fig. 5a**.

Method 2: Semi-supervised AI methods to derive the nine DNEs

The methodologies used in the current study to derive the nine DNEs belong to the semi-
supervised learning algorithms (**Fig. 1a**) pioneered by our group. Refer to a review for details of
this type of modeling. In particular, the current study employed the HYDRA[29] and Surreal-
GAN[14] models.

(a): Surreal-GAN: Surreal-GAN[14] dissects underlying disease-related heterogeneity via a deep
representation learning approach, instead of the discriminative SVM, under the principle of semi-
supervised clustering – the "*1-to-k*" mapping. The methodological advance of this method is that
Surreal-GAN models disease heterogeneity as a continuous dimensional representation, enforces
monotone disease severity in each dimension, and allows the non-exclusive manifestation of all
dimensions in the same participant (**Supplementary eMethod 1a**).
We encapsulated the characteristics of the AD1 and AD2 derived by Surreal-GAN from
the disease-specific population. AD1 represents a "diffuse-AD" dimension characterized by
widespread brain atrophy, whereas AD2, described as a "medial temporal lobe-AD" dimension,
exhibits focal atrophy in the medial temporal lobe (MTL)[1].

(b): HYDRA: HYDRA leverages a widely used discriminative method, i.e., support vector
machines (SVM), to seek the "*1-to-k*" mapping. The novelty is that HYDRA extends multiple
linear SVMs to the non-linear case piecewise, thereby simultaneously serving for classification
and clustering. Specifically, it constructs a convex polytope by combining the hyperplane from k
linear SVMs, separating the CN group from the k subpopulation of the PT (patient) group.
Intuitively, each face of the convex polytope can be regarded to encode each subtype, capturing a
distinct disease effect (**Supplementary eMethod 1b**).
We summarized the main characteristics of the ASD1-3, LLD1-2, and SCZ1-2 derived by
HYDRA in the disease-specific populations. ASD1 showed correlations with reduced brain
volume, decreased cognitive function, and genetic variants related to aging. ASD2 exhibited
enlarged subcortical volumes and was linked to the use of antipsychotic medication. ASD3 was
identified by expanded cortical volumes and higher performance in nonverbal cognitive tasks[2].
LLD1 displayed relatively maintained brain structure without disruptions in white matter
compared to healthy control individuals, whereas LLD2 exhibited extensive brain atrophy,
disruptions in white matter integrity, cognitive decline, and increased severity of depression[3].
SCZ1 exhibited widespread reduction in grey matter volumes, particularly notable in the
thalamus, nucleus accumbens, medial temporal, medial prefrontal/frontal, and insular cortices.
SCZ2 displayed increased volume in the basal ganglia and internal capsule, while other brain
volumes remained relatively normal[4].

Method 3: Imaging analyses

(a): T1-weighted MRI processing: All images were first corrected for magnetic field intensity
inhomogeneity.[87] A deep learning-based skull stripping algorithm was applied to remove extra-
cranial material. In total, 145 IDPs were generated in gray matter (GM, 119 ROIs), white matter

(WM, 20 ROIs), and ventricles (6 ROIs) using a multi☐atlas label fusion method from the
MUSE atlas.[88] The ROIs were fit to the four machine learning models to derive the nine DNEs.
The imaging quality check is detailed in **Supplementary eMethod 2**. The other IDPs derived
from other MRI modalities [i.e., diffusion (category code: 135) and resting-state MRI (data-field
code: 25750)] were downloaded from UKBB.
794
(b): Neuroanatomical pattern of the nine DNEs: We assessed the neuroanatomical patterns
exhibited by the nine DNEs within the general population. Since the DNEs were defined based
on the 119 GM ROIs obtained from T1-weighted MRI scans, we aimed to test whether these
patterns observed in the disease populations were manifested in the general population. To this
end, we used a linear regression model in which each DNE was treated as the dependent
variable, while the ROI, age, age-squared, sex, age x sex interaction, age-squared x sex
interaction, intracranial volume, brain positions in the scanner (lateral, transverse, and
longitudinal; Field ID: 25756-25758), and head motion were considered independent variables
and covariates. We employed the Bonferroni method for multiple comparisons and reported
significant results accordingly.
805
(c): PWAS for the nine DNEs: We performed PWAS to associate the nine DNEs to each of the
611 additional phenotypes. PWAS excluded the 119 GM ROIs utilized to derive the nine DNEs
to prevent any potential circular effects. Instead, the analysis incorporated IDPs from other
modalities, such as diffusion and resting-state functional MRI. The same linear regression
models and multiple comparison corrections were employed as in **Method 3b**.
To check the robustness of our PWAS results, we also performed two sensitivity checks:
i) sex-stratified PWAS for males and females, and *ii*) split-sample PWAS by randomly dividing
the entire population into two splits (sex and age did not significantly differ).
814

Method 4: Genetic analyses

We used the imputed genotype data for all genetic analyses, and our quality check pipeline
resulted in 31,929 participants with European ancestry and 6,477,810 SNPs. First, we excluded
36,394 related individuals (up to 2nd-degree) from the full UKBB sample (*N*~500k) using the
KING software for family relationship inference[89]. We then removed duplicated variants from all
22 autosomal chromosomes. Individuals whose genetically identified sex did not match their
self-acknowledged sex were removed. Other excluding criteria were: i) individuals with more
than 3% of missing genotypes; ii) variants with minor allele frequency (MAF) of less than 1%;
iii) variants with larger than 3% missing genotyping rate; iv) variants that failed the Hardy-
Weinberg test at 1×10^{-10}. The Hardy-Weinberg test removes the SNPs that deviate from the
expected HWE frequency, ensures the integrity of the genetic data, reduces false-positive
findings, and improves the overall robustness of the GWAS results. To adjust for population
stratification,[90] we derived the first 40 genetic principle components (PC) using the FlashPCA
software[91]. Details of the genetic quality check protocol are described elsewhere.
829
(a): GWAS: For GWAS, we ran a linear regression using Plink[92] for each DNE, controlling for
confounders of age, age-squared, sex, age x sex interaction, age-squared x sex interaction, the
first 40 genetic principal components, total intracranial volume, three brain position parameters
in the scanner, and head motion were included, as suggested by a previous study[28]. We adopted

the genome-wide P-value threshold (5×10^{-8}) and annotated independent genetic signals
considering linkage disequilibrium (see below).
To check the robustness of our GWAS results, we also performed several sensitivity
checks: *i*) fastGWA[39,40] for a generalized mix effect model, *ii*) sex-stratified GWAS for males
and females, *iii*) split-sample GWAS by randomly dividing the entire population into two splits
(sex and age did not significantly differ), *iv*) comparison of the GWAS results using the 1348
participants (i.e., 1116 European ancestry) that were collected for baseline and longitudinal scans
from UKBB, *v*) non-European GWAS (*N*=4783), *vi*) independent GWAS on ADNI whole-
genome sequencing data (*N*=1555) on AD1 and AD2, *vii*) concordance with six European
ancestry GWAS from PGC, including AD, ADHD, ASD, BIP, OCD, and SCZ (**Supplementary
eTable 3a**).
845

(b): SNP-based heritability: We estimated the SNP-based heritability (h^2) using GCTA[38] with
the same covariates as in GWAS. GCTA estimates the SNP-based heritability using a method
called restricted maximum likelihood (REML) to quantify the proportion of phenotypic variance
in a trait that the additive effects of all common SNPs can explain, which was claimed to address
the "missing heritability". The main steps involved in GCTA include constructing the genetic
relationship matrix, modeling phenotypic variance, and using REML to estimate the h^2.
852

(c): Annotation of genomic loci: The annotation of genomic loci and mapped genes was
performed via FUMA[93]. For the annotation of genomic loci, FUMA first defined lead SNPs
(correlation $r^2 \leq 0.1$, distance < 250 kilobases) and assigned them to a genomic locus (non-
overlapping); the lead SNP with the lowest P-value (i.e., the top lead SNP) was used to represent
the genomic locus. For gene mappings, three different strategies were considered. First,
positional mapping assigns the SNP to its physically nearby genes (a 10 kb window by default).
Second, eQTL mapping annotates SNPs to genes based on eQTL associations using the GTEx v8
data[94]. Finally, chromatin interaction mapping annotates SNPs to genes when there is a
significant chromatin interaction between the disease-associated regions and nearby or distant
genes[93]. The definition of top lead SNP, lead SNP, independent significant SNP, and candidate
SNP can be found in **Supplementary eMethod 3**.
To determine if a genomic locus is new (i.e., newly discovered in our study), we queried
the candidate SNPs, independent significant SNPs, and top lead SNP in the EMBL-EBI GWAS
Catalog, taking LD into account. A locus is considered new if no previous GWAS has identified
associations with any of these SNPs.
868

(d): Phenome-wide association queries for the identified loci in the GWAS Catalog: We
queried the candidate and significant independent SNPs, fully considering LD (**Supplementary
eMethod 3**), within each locus in the EMBL-EBI GWAS Catalog (query date: 2nd June 2023,
via FUMA version: v1.5.4) to determine their previously identified associations with any other
traits. For these associated traits, we further mapped them into several high-level categories for
visualization purposes. We categorized these traits based on their primary affected organ
systems, with examples including blood pressure under cardiovascular, brain MRI-derived
measures under brain, and AD under neurodegenerative disorders. Other platforms, such as the
GWAS Atlas (https://atlas.ctglab.nl/PheWAS), used a similar categorization approach.
878

(e): Genetic correlation: We used the LDSC[37] software to estimate the pairwise genetic
correlation (g_c) between each pair of DNEs, as well as between the nine DNEs and 9 BAGs of
multiple organ systems from our previous work[17] and 6 neurodegenerative and neuropsychiatric
disorders from PGC (**Supplementary eTable 3a**). We used the precomputed LD scores from the
1000 Genomes of European ancestry. To ensure the suitability of the GWAS summary statistics,
we first checked that the selected study's population was European ancestry; we then guaranteed
a moderate SNP-based heritability h^2 estimate. Notably, LDSC corrects for sample overlap and
provides an unbiased estimate of genetic correlation[95]. Benjamini-Hochberg procedure was
performed to account for multiple comparisons.
888
(f): Bayesian colocalization: We used the R package (*coloc*) to investigate the genetic
colocalization signals between two traits at each genomic locus. We employed the Fully
Bayesian colocalization analysis using Bayes Factors (*coloc.abf*). This method examines the
posterior probability (PP.H4.ABF: Approximate Bayes Factor) to evaluate hypothesis *H4*, which
suggests the presence of a single shared causal variant associated with both traits within a
specific genomic locus. To determine the significance of the *H4* hypothesis, we set a threshold of
PP.H4.ABF>0.8[51]. All other parameters (e.g., the prior probability of p_{12}) were set as default. We
also performed relevant sensitivity analyses to check the robustness of our findings. For each
pair of traits, the genomic locus (*N*>100 SNPs) was defined by default from FUMA on the nine
DNEs, and then the *coloc* package extracted and harmonized the GWAS summary statistics
within this locus for the other trait.
900
(g): Two-sample bidirectional Mendelian randomization: We did not perform causal
inference between each pair of DNEs due to the overlapped populations and low sample sizes in
split-sample analyses.
We employed a bidirectional, two-sample Mendelian randomization using the
TwoSampleMR package[63] to infer the causal relationships between the nine DNEs and the eight
BAGs across nine human organ systems[17] (excluding the brain). The forward and inverse
Mendelian randomization was performed between each trait pair by switching the exposure and
outcome variables. We applied five different Mendelian randomization methods and reported the
results of inverse variance weighted (IVW) in the main text and the four others (i.e., Egger,
weighted median, simple mode, and weighted mode estimators) in the supplement.
We then performed Mendelian randomization between the nine DNEs and eleven chronic
diseases spanning the whole-body system. These diseases include four diseases from PGC (the
ASD and OCD GWAS summary statistics did not provide the allele frequency information) and
seven diseases unbiasedly curated in our previous work[17], which detailed a systematic procedure
to choose the appropriate traits. After harmonizing their GWAS summary statistics (using the
function *harmonise_data* from 2SampleMR), this resulted in 11 clinical traits with at least six
valid IVs (i.e., SNPs). The clinical traits included in our Mendelian randomization are presented
in **Supplementary eTable 11**. Benjamini-Hochberg correction was performed for all tested
traits.
We performed several sensitivity analyses. First, a heterogeneity test was performed to
check for violating the IV assumptions. Horizontal pleiotropy was estimated to navigate the
violation of the IV's exclusivity assumption[96] using a funnel plot, single-SNP Mendelian
randomization approaches, and Mendelian randomization Egger estimator[97]. Moreover, the

leave-one-out analysis excluded one instrument (SNP) at a time and assessed the sensitivity of
the results to individual SNP.
926
(h): PRS calculation for the nine DNEs: We calculated the PRS using the GWAS results from
the split-sample analyses. The weights of the PRS were defined based on split1 data (base data),
and the split2 GWAS summary statistics were used as the target data for PRS calculation. The
QC steps for the base data are as follows: *i*) removal of duplicated and ambiguous SNPs for the
base data; *ii*) clumping the base GWAS data; *iii*) pruning to remove highly correlated SNPs in
the target data; *iv*) removal of high heterozygosity samples in the target data; *v*) removal of
duplicated, mismatching and ambiguous SNPs in the target data. After rigorous QC, we used
PLINK to generate PRS for the split2 population by adopting the classic C+T method (clumping
+ thresholding). To determine the "best-fit" PRS, we performed a linear regression using the PRS
calculated at different P-value thresholds (0.001, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5), controlling for age,
sex, intracellular volume, and the first forty genetic PCs. For each DNE-PRS, we chose the P-
value threshold with the highest incremental R^2 (**Supplementary eFigure 19**).
939   We also tested the PRS-CS[98] method to derive the nine PRS, which infers posterior SNP
effect sizes under continuous shrinkage priors using GWAS summary statistics and an LD
reference panel (i.e., UKBB reference). Compared to the PLINK method, PRS-CS obtained
higher incremental R^2 to explain the 9 DNEs in the split2 data (1.99% vs. 0.52%, P-value=0.003
for two-sample t-test, **Supplementary eFigure 20**). Second, the 9 PRSs from PLINK and PRC-
CS were highly concordant and correlated with each other (Pearson's *r* correlation=0.98, P-
value=0.000007, **Supplementary eFigure 21**). Last but not least, the 9 PRSs from PRS-CS did
not predict well for mental and behavioral disorders (ICD-10 code: F group) and diseases linked
to the central nervous system (ICD-10 code: G group). That is, the highest incremental R^2 was
obtained for ear diseases (H6-H9) using all combined 9 PRSs (**Supplementary eFigure 22**).
Therefore, we chose to use the 9 PRSs derived from PLINK for all results presented in **Fig. 5**.
950
Method 5: Disease, cognition, and mortality outcome prediction.
We employed logistic regression to calculate the incremental R-squared (R^2) statistics of the nine
DNEs and PRSs to predict 14 disease categories (**a**), support vector machines to classify the
healthy control participants from the disease groups (**b**), and Cox proportional hazard model to
predict mortality outcomes (**c**). The patients for the 14 disease categories were defined based on
the ICD-10 code from the UKBB website (Data field: 41270). The healthy control group
included participants without any ICD-10-based disease diagnoses. The cognitive function data
included 8 cogntive scores (Category: 100026), which were detailed in **Supplementary eFile 23**.
The mortality outcome refers to the date of death:
https://biobank.ndph.ox.ac.uk/ukb/field.cgi?id=40000.
961
(a): Pseudo R-squared (R^2) statistics of the logistic regression: We built a null model by
including age, sex, and intracranial volume as predictors and the disease as the outcome variable.
The alternative model took the disease-specific DNE or PRS as one additional predictor. The
incremental R^2 was calculated as the difference between the pseudo R^2 of the alternative model
and that of the null model, implemented by the *PseudoR2* function from the *DescTools* R
package (v 0.99.38). For the nine PRSs, we used the PRS target sample (*N*=15,891). For the nine
DNEs, we calculated the incremental R^2 using the entire UKBB sample (*N*=39,178) and the PRS

target sample (N=15,891). We reported the incremental R^2 of the DNE/PRS in the main
manuscript (**Fig. 5a** and **b**). Other metrics, including R^2 of the null and the alternative model,
sample sizes, and the β values of other covariates, are presented in **Supplementary eFile 20-21**.
972

(b): Support vector machines to classify patients vs. controls: Using the PRS target sample
(N=15,891), we used 10000 participants in a nested cross-validation (CV) procedure (i.e., CV
training/validation/test datasets) to select the hyperparameter C in SVM. In addition, we held out
5581 participants as an independent test dataset. In **Fig. 5c**, we only presented the classification
accuracy from the independent test dataset. The nested cross-validation (CV) procedure[99]
involved an outer loop repeated 50 times, where 80% of the data were randomly selected for
training/validation and 20% for testing. Within each outer loop iteration, an inner loop used 80%
of the training/validation data for a 10-fold training/validation split. Critically, the model trained
on the training/validation/test datasets generalized to the independent test dataset (**Fig. 5c**).
Supplementary eFile 22 contains various metrics, including balanced accuracy, sensitivity,
specificity, negative predictive value (NPV), positive predictive value (PPV), and sample sizes
for the independent dataset (*Ind. accuracy*) and the CV training/validation/test datasets (*CV*
accuracy). We did not statistically compare the performance between different machine learning
models as this is a complex matter without a universal solution. A standard *t*-test on cross-
validation results is too liberal and should not be applied, as shown by Nadeau and Bengio[100].
The corrected resampled *t*-test[100] was proposed, but it depends on the data and the cross-
validation setup.
990

(c): Support vector regression to predict cognitive scores: Using the PRS target sample
(N=15,891), we used 10000 participants in a nested cross-validation (CV) procedure (i.e., CV
training/validation/test datasets) to select the hyperparameter C in SVM. In addition, we held out
5581 participants (some had missing values depending on specific cognitive scores) as an
independent test dataset (*Ind. r*). In **Fig. 5d**, we only presented Pearson's *r* from the independent
test dataset. The same nested CV procedure was used, as mentioned above. Likewise,
Supplementary eFile 23 encompasses a range of metrics, including mean absolute error, P-
values, and sample sizes, pertaining to the independent dataset (*Ind. r)* and the CV
training/validation/test datasets (*CV r)*.
1000

(d): Cox proportional hazard model to predict the date of death: To evaluate the predictive
capacity of individual DNE and PRS for mortality risk, we employed a Cox proportional hazard
model while adjusting for covariates such as age and sex. The hazard ratio (HR) was calculated
and reported as the effect size measure that indicates the influence of each DNE or PRS on
mortality risk. Furthermore, we incrementally added the most predictive DNE or PRS to the Cox
model to determine when the model's performance reached saturation. The concordance index
(CI) was utilized to assess the model's performance using a 5-fold cross-validation procedure.
All survival analyses were conducted using the *lifelines* (v0.25.7) Python package.

Data Availability

1009

1010 The GWAS summary statistics corresponding to this study are publicly available on the
1011 MEDICINE knowledge portal (https://labs-laboratory.com/medicine/). Genomic loci annotation
1012 used data from FUMA (https://fuma.ctglab.nl/). UKBB data can be requested at
1013 https://www.ukbiobank.ac.uk/. GWAS summary data from the Psychiatric Genomics
1014 Consortium (PGC) can be accessed at https://pgc.unc.edu/.

Code Availability

The software and resources used in this study are all publicly available:

- *HYDRA*: https://github.com/anbai106/mlni, DNEs for ASD1-3, LLD1-2, SCZ1-2
- *Surreal-GAN*: https://github.com/zhijian-yang/SurrealGAN, DNEs for AD1-2
- *MLNI*: https://github.com/anbai106/mlni, SVM classification, cognitive regression
- *PLINK*: https://www.cog-genomics.org/plink/, GWAS, PRS
- *FUMA*: https://fuma.ctglab.nl/, gene mapping, genomic locus annotation
- *GCTA*: https://yanglab.westlake.edu.cn/software/gcta/#Overview, heritability estimates, and fastGWA
- *LDSC*: https://github.com/bulik/ldsc, genetic correlation, partitioned heritability
- *TwoSampleMR*: https://mrcieu.github.io/TwoSampleMR/index.html, MR
- *Coloc*: https://chr1swallace.github.io/coloc/, Bayesian colocalization
- *PRS-CS*: https://github.com/getian107/PRScs, PRS
- *Lifelines*: https://lifelines.readthedocs.io/en/latest/, Survival analyses
- *DescTools*: https://cran.r-project.org/web/packages/DescTools/index.html, Incremental R^2 analysis

Competing Interests

None

Authors' contributions

Dr. Wen has full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Wen, Davatzikos

Acquisition, analysis, or interpretation of data: all authors

Drafting of the manuscript: Wen

Critical revision of the manuscript for important intellectual content: all authors

Statistical analysis: Wen

References

References

1. Wen, J. *et al.* Genetic, clinical underpinnings of subtle early brain change along

Alzheimer's dimensions. 2022.09.16.508329 Preprint at

https://doi.org/10.1101/2022.09.16.508329 (2022).

2. Hwang, G. *et al.* Assessment of Neuroanatomical Endophenotypes of Autism Spectrum

Disorder and Association With Characteristics of Individuals With Schizophrenia and the

General Population. *JAMA Psychiatry* (2023) doi:10.1001/jamapsychiatry.2023.0409.

3. Wen, J. *et al.* Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical

Symptoms, and Genetics Among Patients With Late-Life Depression. *JAMA Psychiatry*

(2022) doi:10.1001/jamapsychiatry.2022.0020.

4. Chand, G. B. *et al.* Two distinct neuroanatomical subtypes of schizophrenia revealed using

machine learning. *Brain* **143**, 1027–1038 (2020).

5. Young, A. L. *et al.* Uncovering the heterogeneity and temporal complexity of

neurodegenerative diseases with Subtype and Stage Inference. *Nat Commun* **9**, 4273 (2018).

6. Yang, Z. *et al.* A deep learning framework identifies dimensional representations of

Alzheimer's Disease from brain structure. *Nat Commun* **12**, 7065 (2021).

7. Zhang, X. *et al.* Bayesian model reveals latent atrophy factors with dissociable cognitive

trajectories in Alzheimer's disease. *Proc Natl Acad Sci USA* **113**, E6535–E6544 (2016).

8. Vogel, J. W. *et al.* Four distinct trajectories of tau deposition identified in Alzheimer's

disease. *Nat Med* **27**, 871–881 (2021).

9. Wen, J. *et al.* Multi-scale semi-supervised clustering of brain images: Deriving disease

subtypes. *Med Image Anal* **75**, 102304 (2021).

10.   Ferreira, D., Nordberg, A. & Westman, E. Biological subtypes of Alzheimer disease: A

systematic review and meta-analysis. *Neurology* **94**, 436–448 (2020).

11.   Hodson, R. Precision medicine. *Nature* **537**, S49–S49 (2016).

12.   Davatzikos, C. *et al.* Precision diagnostics based on machine learning-derived imaging

signatures. *Magnetic Resonance Imaging* **64**, 49–61 (2019).

13.   Leonenko, G. *et al.* Identifying individuals with high risk of Alzheimer's disease using

polygenic risk scores. *Nat Commun* **12**, 4506 (2021).

14.   Yang, Z., Wen, J. & Davatzikos, C. Surreal-GAN:Semi-Supervised Representation

Learning via GAN for uncovering heterogeneous disease-related imaging patterns. *ICLR*

(2021).

15.   Wingo, T. S. *et al.* Shared mechanisms across the major psychiatric and neurodegenerative

diseases. *Nat Commun* **13**, 4314 (2022).

16.   Anttila, V. Analysis of shared heritability in common disorders of the brain. *Science* **360**,

eaap8757 (2018).

17.   Wen, J. *et al.* The genetic architecture of biological age in nine human organ systems. *Nat*

Aging 1–18 (2024) doi:10.1038/s43587-024-00662-8.

18.   Wen, J. *et al.* The genetic architecture of multimodal human brain age. *Nat Commun* **15**,

2604 (2024).

19.   Boquetipujadas, A. *et al.* MUTATE: A Human Genetic Atlas of Multi-organ AI

Endophenotypes using GWAS Summary Statistics. 2024.06.15.24308980 Preprint at

https://doi.org/10.1101/2024.06.15.24308980 (2024).

20.   Petersen, R. C. *et al.* Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical

characterization. *Neurology* **74**, 201–209 (2010).

21. Di Martino, A. *et al.* Enhancing studies of the connectome in autism using the autism brain

imaging data exchange II. *Sci Data* **4**, 170010 (2017).

22. Wen, J. *et al.* Subtyping Brain Diseases from Imaging Data. in *Machine Learning for Brain*

Disorders (ed. Colliot, O.) 491–510 (Springer US, New York, NY, 2023). doi:10.1007/978-

1-0716-3195-9_16.

23. Kendler, K. & Neale, M. Endophenotype: a conceptual analysis. *Mol Psychiatry* **15**, 789–

797 (2010).

24. Cannon, T. D. & Keller, M. C. Endophenotypes in the Genetic Analyses of Mental

Disorders. *Annual Review of Clinical Psychology* **2**, 267–290 (2006).

25. Gottesman, I. I. & Gould, T. D. The endophenotype concept in psychiatry: etymology and

strategic intentions. *Am J Psychiatry* **160**, 636–645 (2003).

26. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.

Nature **562**, 203–209 (2018).

27. Alfaro-Almagro, F. *et al.* Image processing and Quality Control for the first 10,000 brain

imaging datasets from UK Biobank. *Neuroimage* **166**, (2018).

28. Elliott, L. T. *et al.* Genome-wide association studies of brain imaging phenotypes in UK

Biobank. *Nature* **562**, 210–216 (2018).

29. Varol, E., Sotiras, A. & Davatzikos, C. HYDRA: Revealing heterogeneity of imaging and

genetic patterns through a multiple max-margin discriminative analysis framework.

NeuroImage **145**, 346–364 (2017).

30. Wen, J. *et al.* Genomic loci influence patterns of structural covariance in the human brain.

Proceedings of the National Academy of Sciences **120**, e2300842120 (2023).

31. Guan, H. & Liu, M. Domain Adaptation for Medical Image Analysis: A Survey. *IEEE*

Trans Biomed Eng **69**, 1173–1185 (2022).

32. Zhang, H., Schneider, T., Wheeler-Kingshott, C. A. & Alexander, D. C. NODDI: Practical

in vivo neurite orientation dispersion and density imaging of the human brain. *NeuroImage*

61, 1000–1016 (2012).

33. Joseph, C., Wang, L., Wu, R., Manning, K. J. & Steffens, D. C. Structural brain changes

and neuroticism in late-life depression: a neural basis for depression subtypes. *Int*

Psychogeriatr **33**, 515–520 (2021).

34. Tian, Y. E. *et al.* Heterogeneous aging across multiple organ systems and prediction of

chronic disease and mortality. *Nat Med* 1–11 (2023) doi:10.1038/s41591-023-02296-6.

35. McCracken, C. *et al.* Multi-organ imaging demonstrates the heart-brain-liver axis in UK

Biobank participants. *Nat Commun* **13**, 7839 (2022).

36. Buniello, A. *et al.* The NHGRI-EBI GWAS Catalog of published genome-wide association

studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res* **47**, D1005–D1012

(2019).

37. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from

polygenicity in genome-wide association studies. *Nat Genet* **47**, 291–295 (2015).

38. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: A Tool for Genome-wide

Complex Trait Analysis. *Am J Hum Genet* **88**, 76–82 (2011).

39. Jiang, L., Zheng, Z., Fang, H. & Yang, J. A generalized linear mixed model association tool

for biobank-scale data. *Nat Genet* **53**, 1616–1621 (2021).

40. Jiang, L. *et al.* A resource-efficient tool for mixed model association analysis of large-scale

data. *Nat Genet* **51**, 1749–1755 (2019).

41.   Wightman, D. P. *et al.* A genome-wide association study with 1,126,563 individuals

identifies new risk loci for Alzheimer's disease. *Nat Genet* **53**, 1276–1282 (2021).

42.   Demontis, D. *et al.* Genome-wide analyses of ADHD identify 27 risk loci, refine the

genetic architecture and implicate several cognitive domains. *Nat Genet* **55**, 198–208

(2023).

43.   Grove, J. *et al.* Identification of common genetic risk variants for autism spectrum disorder.

Nat Genet **51**, 431–444 (2019).

44.   Mullins, N. *et al.* Genome-wide association study of more than 40,000 bipolar disorder

cases provides new insights into the underlying biology. *Nat Genet* **53**, 817–829 (2021).

45.   Trubetskoy, V. *et al.* Mapping genomic loci implicates genes and synaptic biology in

schizophrenia. *Nature* **604**, 502–508 (2022).

46.   International Obsessive Compulsive Disorder Foundation Genetics Collaborative (IOCDF-

GC) and OCD Collaborative Genetics Association Studies (OCGAS). Revealing the

complex genetic architecture of obsessive-compulsive disorder using meta-analysis. *Mol*

Psychiatry **23**, 1181–1188 (2018).

47.   O'Donovan, M. C. What have we learned from the Psychiatric Genomics Consortium.

World Psychiatry **14**, 291–293 (2015).

48.   Cheverud, J. M. A comparison of genetic and pehnotypic correlations. *Evolution* **42**, 958–

968 (1988).

49.   Leeuw, C. A. de, Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: Generalized Gene-

Set Analysis of GWAS Data. *PLOS Computational Biology* **11**, e1004219 (2015).

50.   McCutcheon, R. A., Krystal, J. H. & Howes, O. D. Dopamine and glutamate in

schizophrenia: biology, symptoms and treatment. *World Psychiatry* **19**, 15–33 (2020).

51. Giambartolomei, C. *et al.* Bayesian Test for Colocalisation between Pairs of Genetic

Association Studies Using Summary Statistics. *PLOS Genetics* **10**, e1004383 (2014).

52. Hordyjewska-Kowalczyk, E. *et al.* Functional analysis of novel RUNX2 mutations

identified in patients with cleidocranial dysplasia. *Clin Genet* **96**, 429–438 (2019).

53. Wamsley, B. *et al.* Molecular cascades and cell-type specific signatures in ASD revealed by

single cell genomics. 2023.03.10.530869 Preprint at

https://doi.org/10.1101/2023.03.10.530869 (2023).

54. Ayalew, M. *et al.* Convergent functional genomics of schizophrenia: from comprehensive

understanding to genetic risk prediction. *Mol Psychiatry* **17**, 887–905 (2012).

55. Siokas, V. *et al.* Myelin-associated oligodendrocyte basic protein rs616147 polymorphism

as a risk factor for Parkinson's disease. *Acta Neurologica Scandinavica* **145**, 223–228

(2022).

56. Arnold, S. E. *et al.* Dysregulation of olfactory receptor neuron lineage in schizophrenia.

Arch Gen Psychiatry **58**, 829–835 (2001).

57. Turetsky, B. I., Moberg, P. J., Arnold, S. E., Doty, R. L. & Gur, R. E. Low olfactory bulb

volume in first-degree relatives of patients with schizophrenia. *Am J Psychiatry* **160**, 703–

708 (2003).

58. Almandil, N. B. *et al.* Exome-wide analysis identify multiple variations in olfactory

receptor genes (OR12D2 and OR5V1) associated with autism spectrum disorder in Saudi

females. *Frontiers in Medicine* **10**, (2023).

59. Kuo, P.-H. *et al.* Genome-Wide Association Study for Autism Spectrum Disorder in

Taiwanese Han Population. *PLOS ONE* **10**, e0138695 (2015).

60.   Warnica, W. *et al.* Copy number variable microRNAs in schizophrenia and their

neurodevelopmental gene targets. *Biol Psychiatry* **77**, 158–166 (2015).

61.   Christen-Zaech, S. *et al.* Early Olfactory Involvement in Alzheimer's Disease. *Canadian*

Journal of Neurological Sciences **30**, 20–25 (2003).

62.   Murphy, C. Olfactory and other sensory impairments in Alzheimer disease. *Nat Rev Neurol*

15, 11–24 (2019).

63.   Hemani, G. *et al.* The MR-Base platform supports systematic causal inference across the

human phenome. *eLife* **7**, e34408 (2018).

64.   Sanderson, E. *et al.* Mendelian randomization. *Nat Rev Methods Primers* **2**, 1–21 (2022).

65.   23andMe Research Team *et al.* Genome-wide association study of depression phenotypes

in UK Biobank identifies variants in excitatory synaptic pathways. *Nat Commun* **9**, 1470

(2018).

66.   Navari, S. & Dazzan, P. Do antipsychotic drugs affect brain structure? A systematic and

critical review of MRI findings. *Psychol Med* **39**, 1763–1777 (2009).

67.   Chopra, S. *et al.* Differentiating the effect of antipsychotic medication and illness on brain

volume reductions in first-episode psychosis: A Longitudinal, Randomised, Triple-blind,

Placebo-controlled MRI Study. *Neuropsychopharmacol.* **46**, 1494–1501 (2021).

68.   Zeldovich, L. Cold parenting? Childhood schizophrenia? How the diagnosis of autism has

evolved over time. *Science* doi: 10.1126/science.aau1206 (2018).

69.   Moreau, C. A. *et al.* Dissecting autism and schizophrenia through neuroimaging genomics.

Brain **144**, 1943–1957 (2021).

70.   Fu, Z. *et al.* Dynamic functional network reconfiguration underlying the pathophysiology of

schizophrenia and autism spectrum disorder. *Human Brain Mapping* **42**, 80–94 (2021).

71. Bereczki, E. *et al.* Synaptic markers of cognitive decline in neurodegenerative diseases: a

proteomic approach. *Brain* **141**, 582–595 (2018).

72. Jiang, C.-C. *et al.* Signalling pathways in autism spectrum disorder: mechanisms and

therapeutic implications. *Sig Transduct Target Ther* **7**, 1–36 (2022).

73. Chi, S., Yu, J.-T., Tan, M.-S. & Tan, L. Depression in Alzheimer's disease: epidemiology,

mechanisms, and management. *J Alzheimers Dis* **42**, 739–755 (2014).

74. Dafsari, F. S. & Jessen, F. Depression—an underrecognized target for prevention of

dementia in Alzheimer's disease. *Transl Psychiatry* **10**, 1–13 (2020).

75. Ly, M. *et al.* Late-life depression and increased risk of dementia: a longitudinal cohort

study. *Transl Psychiatry* **11**, 1–10 (2021).

76. Lalousis, P. A. *et al.* Neurobiologically Based Stratification of Recent-Onset Depression

and Psychosis: Identification of Two Distinct Transdiagnostic Phenotypes. *Biological*

Psychiatry **92**, 552–562 (2022).

77. Woo, M. Eyes hint at hidden mental-health conditions. *Eyes hint at hidden mental-health*

conditions https://www.nature.com/articles/d41586-019-01114-9 (2019).

78. Tahsili-Fahadan, P. & Geocadin, R. G. Heart–Brain Axis. *Circulation Research* **120**, 559–

572 (2017).

79. Leng, F. & Edison, P. Neuroinflammation and microglial activation in Alzheimer disease:

where do we go from here? *Nat Rev Neurol* **17**, 157–172 (2021).

80. Murphy, C. E., Walker, A. K. & Weickert, C. S. Neuroinflammation in schizophrenia: the

role of nuclear factor kappa B. *Transl Psychiatry* **11**, 1–13 (2021).

81. Miller, A. H. & Raison, C. L. The role of inflammation in depression: from evolutionary

imperative to modern treatment target. *Nat Rev Immunol* **16**, 22–34 (2016).

82.   Tan, A. H., Lim, S. Y. & Lang, A. E. The microbiome–gut–brain axis in Parkinson disease

1225   — from basic research to the clinic. *Nat Rev Neurol* **18**, 476–495 (2022).

1226   83.   Morais, L. H., Schreiber, H. L. & Mazmanian, S. K. The gut microbiota–brain axis in

1227   behaviour and brain disorders. *Nat Rev Microbiol* **19**, 241–255 (2021).

1228   84.   Tost, H., Champagne, F. A. & Meyer-Lindenberg, A. Environmental influence in the brain,

1229   human welfare and mental health. *Nat Neurosci* **18**, 1421–1431 (2015).

1230   85.   UKBB, U. Ambitious project announced to create the world's largest longitudinal imaging

1231   dataset. https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/news/ambitious-

1232   project-announced-to-create-the-world-s-largest-longitudinal-imaging-dataset.

1233   86.   Wang, R., Chaudhari, P. & Davatzikos, C. Embracing the disharmony in medical imaging:

1234   A Simple and effective framework for domain adaptation. *Med Image Anal* **76**, 102309

1235   (2022).

1236   87.   Tustison, N. J. *et al.* N4ITK: improved N3 bias correction. *IEEE Trans. Med. Imaging* **29**,

1237   1310–1320 (2010).

1238   88.   Doshi, J. *et al.* MUSE: MUlti-atlas region Segmentation utilizing Ensembles of registration

1239   algorithms and parameters, and locally optimal atlas selection. *Neuroimage* **127**, 186–195

1240   (2016).

1241   89.   Manichaikul, A. *et al.* Robust relationship inference in genome-wide association studies.

1242   *Bioinformatics* **26**, 2867–2873 (2010).

1243   90.   Price, A. L., Zaitlen, N. A., Reich, D. & Patterson, N. New approaches to population

1244   stratification in genome-wide association studies. *Nat Rev Genet* **11**, 459–463 (2010).

1245   91.   Abraham, G., Qiu, Y. & Inouye, M. FlashPCA2: principal component analysis of Biobank-

1246   scale genotype datasets. *Bioinformatics* **33**, 2776–2778 (2017).

92. Purcell, S. *et al.* PLINK: A Tool Set for Whole-Genome Association and Population-Based

Linkage Analyses. *Am J Hum Genet* **81**, 559–575 (2007).

93. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and

annotation of genetic associations with FUMA. *Nat Commun* **8**, 1826 (2017).

94. The GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* **45**,

580–585 (2013).

95. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits.

Nat Genet **47**, 1236–1241 (2015).

96. Bowden, J. *et al.* A framework for the investigation of pleiotropy in two-sample summary

data Mendelian randomization. *Stat Med* **36**, 1783–1802 (2017).

97. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid

instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol*

44, 512–525 (2015).

98. Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C. A. & Smoller, J. W. Polygenic prediction via

Bayesian regression and continuous shrinkage priors. *Nat Commun* **10**, 1776 (2019).

99. Wen, J. *et al.* Convolutional neural networks for classification of Alzheimer's disease:

Overview and reproducible evaluation. *Medical Image Analysis* **63**, 101694 (2020).

100. Nadeau, C. & Bengio, Y. Inference for the Generalization Error. *Machine Learning* **52**,

239–281 (2003).

1266

Acknowledgments

We want to express our sincere gratitude to the UK Biobank team for their invaluable contribution to advancing clinical research in our field. We thank the Psychiatric Genomics Consortium (PGC: https://pgc.unc.edu/) for generously sharing the GWAS summary statistics with the scientific community. This study used the UK Biobank resource under Application Numbers 35148 (CD) and 60698 (AZ). We also gratefully acknowledge the support of the iSTAGING consortium, funded by the National Institute on Aging through grant RF1 AG054409 at the University of Pennsylvania (CD). Additionally, we acknowledge the funding program from the Rebecca L. Cooper Foundation at the University of Melbourne (AZ).